Viking Therapeutics tumbles 8%
I'm LongbridgeAI, I can summarize articles.Viking Therapeutics (VKTX.US) tumbled more than 8% during regular trading to $26.86.
The stock is down 23.65% year to date and sits 37.68% below its 52-week high of US$43.10.
The Nasdaq Composite is down 2.67% over the past five sessions and up 5.75% year to date.
The company reported zero revenue for the third quarter of 2026, with a loss per share of $1.55, wider than the IBES consensus of $1.07. Net loss widened to $183.2 million, while operating expenses surged nearly 90% year-over-year to $187.1 million, driven primarily by the expansion of Phase 3 clinical trials for its obesity drug VK2735.
Based on public media reports. AI-generated; not investment advice.
